Perspective Therapeutics CATX
NYSE CATX
$2.98 -0.14 (-4.49%)
As of: Sep 9, 2026 · 3:59 PM EDT

Perspective Therapeutics (CATX) Acquisitions (2023)

Perspective Therapeutics' (CATX) quarterly Acquisitions came in at $2.7 million in Q1 2023.

Analysis

Perspective Therapeutics (CATX) Acquisitions (2023) Analysis & Trends

Perspective Therapeutics has disclosed Acquisitions across 1 years of filings, most recently posting $2.7 million for Q1 2023.

  • In Q1 2023, Acquisitions changed N/A year-over-year to $2.7 million; the TTM figure through Dec 2023 stood at $2.7 million (changed N/A YoY), while the FY2023 annual figure was $2.7 million, changed N/A from the prior year.
  • Acquisitions came in at $2.7 million for Q1 2023 at Perspective Therapeutics.
  • In the past five years, Acquisitions ranged from a high of $2.7 million in Q1 2023 to a low of $2.7 million in Q1 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Acquisitions (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn -
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 11.21 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn -
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn -
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn -
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn -
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn -
10 Perspective Therapeutics 358.23 Mn 358.23 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 2.70 Mn